{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Galectin Therapeutics, Inc. technically bullish or bearish?
As of June 18, 2025, the trend is mildly bullish, supported by weekly MACD and Bollinger Bands, despite some bearish signals from the monthly MACD and KST, with caution advised due to a bearish RSI on the weekly timeframe.
Who are in the management team of Galectin Therapeutics, Inc.?
As of March 2022, the management team of Galectin Therapeutics, Inc. includes Richard Uihlein (Independent Chairman), Joel Lewis (CEO), Adam Allgood (Executive Director of Clinical Development), and several directors including James Czirr, Harold Shlevin, Gilbert Amelio, and Kary Eldred. They oversee the company's strategic direction and operations.
What does Galectin Therapeutics, Inc. do?
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases and cancer, with a market cap of approximately $151.27 million. The company reported a net loss of $10 million in its most recent quarter.
How big is Galectin Therapeutics, Inc.?
As of Jun 18, Galectin Therapeutics, Inc. has a market capitalization of 151.27 million and reported net sales of 0.00 million with a net profit of -45.19 million over the last four quarters. The company's shareholder's funds were -103.07 million, with total assets of 17.50 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
